product name Fluticasone propionate
Description: Fluticasone Propionate (also known as CCI-187881) is a synthetic glucocorticoid used for the treatment of non-allergic and allergic rhinitis. Fluticasone propionate belongs to a class of drugs known as corticosteroids, specifically glucocorticoids, which are hormones that predominantly affect the metabolism of carbohydrates and, to a lesser extent, fat and protein. It is used to treat asthma, allergic rhinitis, nasal polyps, various skin disorders and Crohns disease and ulcerative colitis. It is also used to treat eosinophilic esophagitis.
References: Int Immunol. 2005 Nov;17(11):1473-81; Vet Immunol Immunopathol. 2002 Mar;85(3-4):147-58.
500.57
Formula
C25H31F3O5S
CAS No.
80474-14-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 100 mg/mL (199.8 mM)
Water: <1 mg/mL
Ethanol: 5 mg/mL (10.0 mM)
Solubility (In vivo)
Synonyms
CCI-187881
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19422567
| In Vitro |
In vitro activity: Fluticasone propionate (1 pM) inhibits the constitutive and TGF-beta-induced expression of alpha-SMA in human lung myofibroblasts. Fluticasone propionate blocks the TNF-alpha-induced nuclear translocation of the pro-inflammatory transcription factor NF-kappaB in human lung myofibroblasts. Fluticasone propionate inhibits in lung myofibroblasts, at a very early stage of differentiation, the activation of Janus kinase/STAT pathways induced by IL-13 (tyrosine kinase 2, STAT1, STAT3, STAT6, mitogen-activated protein kinase). Fluticasone propionate still displays a potential anti-inflammatory activity even if it only inhibits tyrosine kinase 2 phosphorylation in mildly or fully differentiated myofibroblastic cultures. Fluticasone propionate inhibits constitutive and TGF-beta-induced expression of alpha-smooth muscle actin, the main marker of myofibroblastic differentiation, both in very early and in mild differentiated myofibroblasts. Fluticasone propionate displays an additional powerful anti-inflammatory effect, decreasing nuclear translocation of NF-kappaB independent of the degree of myofibroblastic differentiation. Fluticasone propionate inhibits allergen-induced T-cell proliferation, expression of IL-3, IL-5 and GM-CSF mRNA, and secretion of the corresponding proteins in a concentration-dependent fashion. Fluticasone propionate has the potential markedly to inhibit allergen-induced T-cell production of asthma-relevant cytokines. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Fluticasone propionate administrated after induction of a severe heaves exacerbation results in complete resolution of clinical signs, normalization of pulmonary function tests, and significant decrease in bronchoalveolar lavage (BAL) neutrophilia in horse. |
| Animal model | |
| Formulation & Dosage | |
| References | Int Immunol. 2005 Nov;17(11):1473-81; Vet Immunol Immunopathol. 2002 Mar;85(3-4):147-58. |
Dorsomorphin (dihydrochloride)
